Skip to main content
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. — Investor Relations & Filings

Ticker · NAUT ISIN · US63909J1088 US Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2022-05-10 Director's Dealing
Country US United States of America
Listing US NAUT

About Nautilus Biotechnology, Inc.

https://www.nautilus.bio/

Nautilus Biotechnology, Inc. is a life sciences company developing a platform to revolutionize proteome analysis. The company's Proteome Analysis Platform is designed to quantify proteins at the single-molecule level, leveraging a proprietary method called Iterative Mapping. This technology aims to provide high-resolution views of billions of individual protein molecules and their modifications (proteoforms). The platform is being developed with two key modalities: broadscale proteomic analysis for comprehensive proteome exploration and targeted proteoform analysis for in-depth examination of protein variants. The intended applications include accelerating drug target identification, discovering more effective biomarkers, and enabling foundational biological research by making advanced proteomics more accessible to the scientific community.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-05-10 English
FORM 4
Director's Dealing
2022-05-05 English
FORM 4
Director's Dealing
2022-05-05 English
424B3
Interim / Quarterly Report Classification · 100% confidence The document is a Quarterly Report on Form 10-Q filed with the SEC for the quarterly period ended March 31, 2022. It contains detailed financial statements, management discussion and analysis, risk factors, and other comprehensive financial information typical of a quarterly report. The presence of condensed consolidated financial statements and management's discussion confirms it is a substantive financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2022-05-03 English
10-Q
Interim / Quarterly Report Q1 2022
2022-05-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated May 3, 2022, by Nautilus Biotechnology, Inc. It specifically mentions Item 2.02 "Results of Operations and Financial Condition" and states that a press release reporting financial results for the quarter ended March 31, 2022, is furnished as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of quarterly financial results via a press release. The length is 3438 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. According to the classification rules, initial announcements of quarterly financial results (key highlights only) correspond to an Earnings Release (ER). Therefore, this document should be classified as an Earnings Release (ER).
2022-05-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.